CXCR4 and neoplasm: To overcome the issue of monotherapy resistance, researchers have explored the combination of PD1/PD-L1 inhibitors with other therapies, such as TKIs, CTLA-4 inhibitors, and emerging CXCR4 inhibitors, demonstrating higher efficacy and anti-tumor activity.